What Is the Life Expectancy With a CRT Device?

People with advanced heart failure who receive a cardiac resynchronization therapy (CRT) device can expect a meaningful extension of life compared to medical therapy alone, though individual outcomes vary widely depending on how well the heart responds and what other health conditions are present. Across five landmark trials, CRT reduced the risk of death by roughly 29% on average, and a large registry study found that about 45% of CRT recipients were still alive at the ten-year mark. Those numbers, however, are population averages that mask enormous variation from person to person.

What the Major Trials Tell Us About Survival

The strongest evidence for CRT’s survival benefit comes from randomized trials conducted over the past two decades. A pooled analysis of five landmark trials covering more than 6,500 patients found an average hazard ratio for death of 0.71, meaning CRT reduced the risk of dying during the trial periods by about 29% compared to standard therapy.¹ That benefit appears to persist well beyond the trial windows. Long-term follow-up of the RAFT trial, one of the largest CRT studies, showed that the survival advantage of CRT-D over a standard defibrillator alone was sustained through nearly 14 years of follow-up.²

For patients with mild heart failure and left bundle-branch block specifically, the benefit was even more dramatic. In a seven-year follow-up of the MADIT-CRT trial, about 18% of patients randomized to CRT-D had died, compared with 29% in the defibrillator-only group, representing a 41% reduction in the risk of death.³ These trial results, however, reflect carefully selected patients. Real-world outcomes tend to be somewhat less favorable because the general CRT population is older and sicker than clinical trial participants.

Real-World Survival Numbers

Registry data give a more grounded picture. A study tracking more than 50,000 CRT implantations found that over a median follow-up of about 2.7 years, roughly 28% of patients had died.⁴ Another single-center analysis that followed patients for a decade reported cumulative survival rates of about 91% at two years, 71% at five years, and 45% at ten years.⁵ Those numbers reflect a population with advanced heart failure, a condition that, without any device therapy, carries a much grimmer prognosis. The fact that nearly half of patients with severe heart failure were still alive a full decade after CRT implantation is a genuinely encouraging finding.

Response to CRT Is the Single Biggest Factor

Not everyone’s heart responds to CRT the same way, and how much your heart improves after implantation is the strongest predictor of how long you will live with the device. Researchers typically classify patients based on how much the heart shrinks back toward normal size, a process called reverse remodeling. In one classification scheme, about 22% of patients were “super-responders” whose hearts shrank dramatically, 35% were standard responders, 21% showed minimal change, and 22% actually got worse.⁶

The survival gap between these groups is stark. At five years, about 82% of super-responders were alive and free of needing a heart transplant or a mechanical pump, compared with 70% of standard responders and only 48% of non-responders.⁷ Super-responders can see their heart function improve so much that their long-term outlook approaches excellent, though cardiac events can still occur even when the heart appears to have recovered.⁸ The two-year hospitalization-free survival rate was 96% for super-responders versus 70% for patients whose hearts worsened after the device was placed.⁹

The frustrating part is that predicting response before implantation remains imperfect. Certain factors do tilt the odds, though, which brings us to the characteristics that shape your personal prognosis.

Ischemic Versus Non-Ischemic Heart Failure

The cause of your heart failure matters. Patients whose heart failure stems from coronary artery disease (ischemic cardiomyopathy) tend to fare worse after CRT than those whose heart muscle weakened for other reasons (non-ischemic cardiomyopathy). One recent study with very long follow-up found average post-CRT survival of about 16 years for non-ischemic patients compared with about 9 years for ischemic patients in a matched cohort.¹⁰ That difference is substantial, and it persists even after adjusting for age and other health conditions.

The reasons for this gap are intuitive. Coronary artery disease is a progressive condition, meaning new blockages can develop and further damage the heart over time. Non-ischemic patients, by contrast, often have a form of heart muscle disease that is more amenable to the kind of electrical correction CRT provides. The heart tends to remodel more favorably in non-ischemic patients.¹¹ An ischemic cause of heart failure has been identified as an independent predictor of higher cardiovascular death and hospitalization after CRT.¹²

QRS Width and Bundle-Branch Block Pattern

Your electrocardiogram before implantation gives strong clues about how much benefit you will get. The widest QRS complexes and a left bundle-branch block (LBBB) pattern predict the best outcomes. Among older heart failure patients receiving CRT, those with LBBB and a QRS duration of 150 milliseconds or wider had a three-year mortality of about 21%, while those without LBBB and a QRS under 150 ms had a rate of about 32%.¹³

Right bundle-branch block (RBBB), on the other hand, predicts a less favorable outcome. A large Medicare analysis found that the combination of RBBB and ischemic cardiomyopathy carried roughly twice the risk of death compared with LBBB and non-ischemic cardiomyopathy.¹⁴ Wider QRS duration predicted better results in LBBB patients but made no difference in RBBB patients. This is one reason current guidelines are most enthusiastic about CRT for patients with LBBB and very wide QRS complexes.

Women Tend to Do Better

One of the more consistent findings in CRT research is that women derive a greater survival benefit than men. In a large nationwide cohort, women receiving CRT defibrillators had roughly a 27% lower adjusted risk of death compared to men, and women receiving CRT pacemakers had about a 31% lower adjusted risk.¹⁵ This gap actually widened over time rather than narrowing.

The MADIT-CRT trial painted an even more dramatic picture. Women in that trial had a 69% reduction in the combined risk of death or heart failure with CRT-D, compared with a smaller benefit in men.¹⁶ Women consistently showed greater reverse remodeling of the heart, which likely explains their better long-term outcomes. Interestingly, in women the addition of a defibrillator component (CRT-D versus CRT-P) did not add a significant survival benefit, whereas it did in men.¹⁷ Despite these better outcomes, women remain underrepresented among CRT recipients.¹⁸

Age and Kidney Disease

Older age does not disqualify you from benefiting. Even patients in their eighties have been shown to achieve meaningful improvement in symptoms and heart function after CRT, with survival similar to the general age-matched population.¹⁹ The device cannot add decades of life for someone who is already 85, but it can restore functional capacity and keep heart failure from being what shortens their remaining years.

Kidney disease, however, is a strong independent predictor of worse outcomes. Among CRT patients, those with normal kidney function had three-year survival of about 72%, compared with 57% for those with chronic kidney disease.²⁰ By ten years, roughly 70% of patients with severe kidney disease had died, compared with estimated five-year mortality rates of about 33–36% for those with normal or mildly reduced kidney function.²¹ Kidney function should be part of the conversation when evaluating expected benefit from CRT.

Does Adding a Defibrillator Make a Difference?

CRT devices come in two varieties: CRT-P (pacemaker only) and CRT-D (pacemaker plus a built-in defibrillator that can shock a dangerously fast heart rhythm). In the large 50,000-patient registry, CRT-D was associated with lower mortality than CRT-P after adjusting for patient differences.²² But the RESET-CRT project, which used more rigorous statistical balancing to make the two groups comparable, found no survival difference between CRT-D and CRT-P once patient characteristics were truly matched.²³

The answer seems to depend on who you are. Among patients with ischemic cardiomyopathy, the defibrillator component appears to add a meaningful survival benefit, with one study showing a 30% reduction in death compared to CRT-P alone in that subgroup.²⁴ In non-ischemic patients, the defibrillator did not improve survival over CRT-P in the same study. And as noted earlier, the defibrillator’s added benefit appears less clear in women. This debate remains one of the most active in the field.

Why Medications Still Matter After Implantation

A CRT device works best when combined with optimal drug therapy. Heart failure medications including beta-blockers, ACE inhibitors or related drugs, and mineralocorticoid receptor antagonists each independently reduce the risk of death. In a study of CRT-D recipients, each additional guideline-directed medication a patient was taking was associated with a 30% reduction in mortality.²⁵ The device and the drugs are complementary, and patients who are on the best available medical regimen get the most out of their CRT device.

Atrial fibrillation is another factor that can quietly erode the benefit of CRT. The device works by pacing both sides of the heart simultaneously, and it needs to be the one controlling the heart rhythm for most beats. When atrial fibrillation takes over, the percentage of paced beats drops, and so does the benefit. Patients with a history of atrial fibrillation whose biventricular pacing fell below 98% had roughly double the risk of death or heart transplant compared to patients without atrial fibrillation.²⁶ Maintaining a high pacing percentage, sometimes requiring additional procedures to control atrial fibrillation, is critical for long-term success.

Remote Monitoring and Device Complications

Modern CRT devices can transmit data to your care team wirelessly, and there is evidence that this kind of remote monitoring improves outcomes. A large observational study of nearly 70,000 ICD and CRT-D patients found that those receiving remote follow-up had significantly higher one-year and five-year survival rates than those followed only through in-office clinic visits.²⁷ A smaller study specifically in CRT-D patients showed lower cardiovascular death in the remote monitoring group.²⁸ The likely explanation is that early detection of problems like lead displacement, atrial fibrillation, or worsening fluid status allows intervention before a hospitalization becomes necessary.

Device complications are a reality of living with CRT. One Italian registry found that infections occurred at a rate of about 1% per year, and the risk of infection roughly doubled after device replacement procedures compared to the initial implant. Left ventricular lead dislodgements happened at about 2.3% per year. The reassuring finding, though, was that these complications did not increase the risk of death; patients who needed surgical revision had survival comparable to those who did not.²⁹ Generator replacements, which are needed every several years when the battery wears down, carry a low but non-zero complication rate.³⁰

How CRT Patients Eventually Die

Understanding the typical causes of death after CRT is useful context for thinking about longevity. In a study of very long-term CRT outcomes, progressive heart failure was the leading cause of death, accounting for about 43% of deaths in CRT-P patients and 53% in CRT-D patients. Roughly a third of deaths in both groups were due to non-cardiovascular causes, things like cancer, infection, or organ failure. Sudden cardiac death, the kind of event a defibrillator is designed to prevent, made up a very small proportion of late deaths regardless of whether the patient had a defibrillator.³¹

This pattern has implications for patients who survive the first several years. As time goes on, the risk shifts away from sudden electrical events and toward gradual heart failure progression and non-cardiac diseases. For patients whose hearts have responded well to CRT, the focus of long-term care often broadens beyond the heart itself.

Newer Pacing Approaches on the Horizon

Conventional CRT works by placing one lead in the right ventricle and a second in a vein on the outside of the left ventricle. A newer approach called left bundle-branch pacing (LBBP) aims to stimulate the heart’s own conduction system more directly. A meta-analysis found that LBBP-CRT achieved greater QRS narrowing, better improvement in heart pump function, and lower pacing thresholds compared with conventional biventricular pacing.³² A small randomized trial also found significantly greater improvement in heart pump strength at six months with LBBP-CRT.³³

However, the largest randomized trial to date, the LEFT-BUNDLE-CRT trial, could not demonstrate that LBBP-CRT was at least as good as conventional biventricular pacing in patients with typical LBBB. Both approaches yielded high response rates and similar clinical outcomes.³⁴ The technique is promising and is already being used in practice, particularly when conventional lead placement is technically difficult, but it is too early to say whether it will meaningfully change long-term survival numbers.

Planning for the Later Years With a CRT-D

For patients with CRT-D devices, there is an important conversation that often gets postponed too long: what to do about the defibrillator function as health declines. The shock feature is designed to rescue you from a lethal rhythm, which is valuable when survival and quality of life are the goals. But as a patient approaches the end of life from progressive heart failure or another terminal illness, those shocks can become painful and distressing without meaningfully prolonging a life worth living. Guidelines from the British Heart Rhythm Society recommend that patients be given the opportunity to discuss and choose deactivation of the shock function as part of end-of-life planning.³⁵ Turning off the shock function does not turn off the pacing function; the CRT part continues to help the heart pump more efficiently and keep the patient comfortable. Despite the availability of this option, awareness among patients and non-specialist clinicians remains low, and many patients receive avoidable shocks in their final days because the conversation never happened.³⁶